arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Tarsus Pharmaceuticals, Inc.

TARS
$74.29 ▼ -2.84 (-3.68%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
32 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tarsus Pharmaceuticals, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.2B
Dividend Yield
Revenue Growth 69.4%
Op. Margin -11.4%
ROIC -3.7%
FCF / Share $1.32
Trailing P/E
Price / Book 9.3x
FCF Yield 1.8%
Debt / Equity 0.21
info Valuation on last close. End-of-day price, Sep 23, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$173.91M
↑ +69.4%
Net Income Profit after all expenses
$-6.97M
↑ +72.3%
Operating Margin Operating profit as % of sales
-11.4%
↓ -203.0% 12th
FCF / Share Free cash flow per share
$1.32
↑ +285.7%
Long-Term Debt Long-term obligations
$72.76M
— +0.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
28
Financial Health
52
Cash Quality
33

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters